Alopecia areata - Alopesi Zòn Nan
☆ Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Yo wè Alopesi Zòn Nan (Alopecia areata) sou do po tèt la. Nan ka tipik, li parèt toudenkou ak yon sifas ki konplètman lis ak yon gwosè 2-3 cm.
References
Alopecia areata se yon kondisyon kote sistèm iminitè ou atake folikulèr cheve ou yo, ki mennen nan pèt cheve tanporè san sikatris. Li ka parèt tankou plak pèt cheve oswa afekte tout po tèt ou oswa kò, enpak sou apeprè 2% nan moun nan kèk etap nan lavi yo. Koupab prensipal la sanble se yon pann nan pwoteksyon natirèl la alantou folikulèr cheve yo.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata se yon kondisyon kote sistèm iminitè a atake folikulèr cheve yo, sa ki lakòz pèt cheve sou po tèt la ak lòt pati ki gen cheve nan kò a. Li afekte anviwon 2% moun atravè lemond. Pandan ke li ka rive nan nenpòt laj, li pi komen nan timoun pase granmoun (1. 92% vs. 1. 47%) . Fi, espesyalman moun ki gen plis pase 50, gen tandans fè eksperyans li plis pase gason. Enjekte kortikoterapi dirèkteman nan zòn ki afekte yo montre pi bon rezilta pase aplike yo lokalman.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopesi areata yo kwè se yon maladi otoiminitè ki gen rapò ak sistèm iminitè a nan folikulèr cheve yo. Mekanis kache a enplike nan echèk kò a pou rekonèt pwòp selil li yo, ak destriksyon iminitè ki vin apre nan pileu cheve a.
○ Tretman - Medikaman OTC
Gen kèk moun ki gen alopési ki twò grav refè nan yon ane san tretman. Sepandan, pifò moun fè eksperyans repetition nan sit o aza sou po tèt la.
#Hydrocortisone cream
○ Tretman
Piki esteroyid entralesional yo se tretman ki pi efikas. Iminoterapi ka eseye si gwo zòn nan po tèt la afekte.
#Triamcinolone intralesional injection
#DPCP immunotherapy